TOP > 外国特許検索 > VACCINE PREPARATION AGAINST MALARIAL PARASITE INFECTION

VACCINE PREPARATION AGAINST MALARIAL PARASITE INFECTION

外国特許コード F150008262
掲載日 2015年3月27日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP002071
国際公開番号 WO 2014171116
国際出願日 平成26年4月10日(2014.4.10)
国際公開日 平成26年10月23日(2014.10.23)
優先権データ
  • 特願2013-087431 (2013.4.18) JP
発明の名称 (英語) VACCINE PREPARATION AGAINST MALARIAL PARASITE INFECTION
発明の概要(英語) The present invention relates to a vaccine preparation against malarial parasite infection. More specifically, the invention relates to a vaccine preparation containing a liposome preparation in which a soluble protein derived from a malarial parasite is encapsulated by a liposome having on the surface an oligosaccharide capable of bonding to a sugar chain-recognizing molecule on the surface of an antigen presenting cell.
従来技術、競合技術の概要(英語) BACKGROUND ART
Malaria in the tropical, subtropical areas 70 distributed or more countries of protozoan infection. 3-5 million year all over the world, an accumulated total of about 8 million patients infected with malaria, 100-150 million people have been reported to die of malaria.
A single-cell organism is a pathogen of malaria in a malaria parasite, Plasmodium falciparum, P. falciparum (p. vivax) 3, 4 P. falciparum (p. malariae), oval (p. ovale) 4 of the malaria parasite species present. In particular Plasmodium falciparum malaria by heavy symptoms.
Plasmodium parasite, by female Anopheles mosquitoes to a bloodsucking with transmission, an anti-malarial sporozoite carrying human with respect to the host. Sporozoite is, carried by the blood to the liver, hepatocytes grown in, changes to the life cycle of the merozoite that is in the following forms. The infected hepatocytes rupture, merozoite is released in the blood stream. Merozoite infected red blood cells is then, in part, in red blood cells to male and female reproductive the mother cell. And another is a bloodsucking mosquitoes of infection of the host, supplied with the male and female reproductive cell is, in the interior of the female mosquitoes to fuzed liverstage. This is a bloodsucking mosquitoes can be the next host, host yet another liverstage-transmitted.
Naturally infected with the malaria parasite in the human host, anti-malaria antibody is produced. However, only an antibody is produced, the malaria parasite as protective immunity (humoral immunity) is the ability to neutralize not held, having a memory characteristic sufficient also cell-mediated immunity is not caused. As a result of infection can occur many times, complicating disease treatment and prevention method according to the embodiment.
The highest malaria as a vaccine is that the protective effect is confirmed, the malaria parasite infectious forms liverstage is inactivated by irradiation of radiation is a vaccine. However, because of the need for a high degree of production facility, in a region to develop and unsuited for widespread use. Therefore, a powerful and simple preparation is the development of new vaccines has been expected. However, a primate human malaria is basically does not infect only, in order to confirm the effectiveness of the vaccine, monkey, or the experiments using human, mouse malarial parasites to infect mouse cannot be performed only by the simulated experiments. Therefore, the development of new vaccines for human malarial are extremely difficult to (non-patent document 1, non-patent document 2).
Therefore, the inactivated sporozoite vaccine antigens which have an effect equivalent to that of purified protein, produced as a subunit vaccine (the peptide) of the water-based and is considered to be practical. Up to now, some of the candidate molecule is found in the malaria vaccine, a portion of the drug in a clinical is started, and to confirm the effectiveness has not been reported (non-patent document 3).
In addition, compared to the live vaccine, productivity and storage of handling such as very simple DNA vaccine is known as a vaccine. Possible DNA vaccine is easy to manufacture since, against early mutation, improved quickly can be to provide a vaccine. However, the vaccine is effective against malaria falciparum DNA has not been developed yet (non-patent document 4).
In this way, effective against malaria vaccine is currently not obtained. Key is malaria vaccine development, how strong immunogenicity and antigen-presenting cells is transferred to the antigen protein, and a sufficient antigen-specific antibody production to induce cell-mediated immunity.
Delivery of the antigen protein is, coated with oligomannose sugar chain such as a liposome, a liposome having the oligosaccharide antigen on the surface of the encapsulate is known (patent document 1, non-patent document 5-8). The inventors have found that, on the surface of a liposome having the oligosaccharide to soluble antigen derived from a protozoan neospora sealed (Neospora caninum), mice can be immunized in this liposome, neospora Th1 type immunity induced significantly with respect to the protozoa, vertical transmission and the body to control the propagation of the protozoa can be reported (patent document 2, non-patent document 9). However, a P. falciparum antigen will be, yet such formulation not attempt was made.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE
  • TOKAI UNIVERSITY EDUCATIONAL SYSTEM
  • 発明者(英語)
  • NISHIKAWA, Yoshifumi
  • KURODA, Yasuhiro
  • KOJIMA, Naoya
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close